2025-12-13 - Analysis Report
Okay, let's break down the analysis of Hims & Hers Health Inc. (HIMS).

**0) Report Structure:**

This report will first present the raw data, followed by analysis of each data point.  Finally, a comprehensive summary will tie everything together.

**1) Return Rate Comparison:**

*   **Ticker:** HIMS
*   **Company Overview:** Hims & Hers Health Inc. is a telehealth company offering personalized health and wellness solutions.
*   **HIMS Cumulative Return:** 144.59%
*   **VOO (S&P 500) Cumulative Return:** 76.33%
*   **Divergence:**
    *   Current: 64.1
    *   Relative Divergence: 36.8%

**Analysis:**

HIMS has significantly outperformed the S&P 500 (VOO) over the period. The relative divergence of 36.8% suggests the current divergence is not near its historical highs, indicating the outperformance *could* continue, but is not necessarily guaranteed. The divergence value by itself doesn't mean that HIMS is doing better than S&P 500.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD   | Alpha   | Beta   | Cap(B) |
|------------|---------|-------|---------|--------|--------|
| 2019-2021  | -42.0%  | 74.4% | -81.0%  | 0.0   | 1.5    |
| 2020-2022  | -19.0%  | 78.6% | -18.0%  | -0.0  | 1.4    |
| 2021-2023  | -65.0%  | 78.6% | -67.0%  | -0.1   | 2.0    |
| 2022-2024  | 119.0% | 79.4% | 98.0%  | -0.0  | 5.4    |
| 2023-2025  | 149.0% | 80.8% | 82.0%  | 0.1   | 8.5    |

**Analysis:**

*   **CAGR:** The Compounded Annual Growth Rate shows volatile performance. The stock suffered significant losses in prior periods, followed by strong growth in recent years.
*   **MDD:** The Maximum Drawdown is consistently high, indicating significant risk and volatility.
*   **Alpha:** Alpha measures the investment's performance compared to the market. The trend changed from significantly underperforming the market to outperforming.
*   **Beta:** Beta measures volatility compared to the market. Beta values close to 0 suggest HIMS has not been strongly correlated with the broader market during these periods.
*   **Cap(B):** The capitalization has been increasing.

**2) Recent Stock Price Fluctuations:**

*   **Close:** 37.88
*   **Last Market:** price = 37.21, previousClose = 37.77, change = -1.48
*   **5-day SMA:** 39.208
*   **20-day SMA:** 37.4005
*   **60-day SMA:** 46.8318

**Analysis:**

*   The stock closed at 37.88 and the last market price was 37.21, indicating that the price went down.
*   The 5-day SMA is above the 20-day SMA, which is above the current price, implying a short-term downtrend or potential for further price decline. The 60-day SMA is significantly higher, reinforcing the notion that the stock price is in a downtrend.

**3) RSI, PPO, and Expected Return:**

*   **MRI:** 0.8 (Medium Investment Recommended)
*   **RSI:** 55.02
*   **PPO:** 1.70
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (26 shares - Very Safe - MRI:0.90) Monthly invest 1.3% of total investment ($1,000.00)
*   **Recent Divergence Change:** -1.0 (Short-term decline)
*   **Expected Return:** 23.1%

**Analysis:**

*   **MRI:** A Medium Investment recommendation suggests moderate risk.
*   **RSI:** An RSI of 55.02 is neutral, neither overbought nor oversold.
*   **PPO:** A PPO of 1.70 indicates that the short-term moving average is above the long-term moving average, signaling a potential uptrend.
*   **Hybrid Signal:** This signal recommends buying, viewing the stock as "Very Safe" with a MRI of 0.90.
*   **Recent Divergence Change:** This confirms the recent short-term price decline observed in the moving averages.
*   **Expected Return:** The 23.1% expected return is promising for long-term investors.

**4) Recent News & Significant Events:**

*   **Share Repurchase Program:** Hims & Hers announced a $250 million share repurchase program, often viewed positively as it can boost earnings per share and signal confidence in the company's future.
*   **Analyst Sentiment:** News articles highlight concerns about the stock's recent decline and debate whether it's a buying opportunity or time to sell.
*   **UK Expansion:** The expansion of weight-loss treatments into the UK is a positive development, indicating growth and market diversification.
*   **Stock drop:** $HIMS is down 5% today.

**Analysis:**

The news is mixed. The share repurchase program and UK expansion are positive catalysts. However, the articles discussing the stock's decline and uncertainty suggest caution.

**4-2) Analyst Opinions:**

*   **Consensus:** Hold
*   **Mean Rating:** 2.93 (~Hold)
*   **Target Price:** 44.67 (avg) / 85.00 (high) / 25.00 (low)

**Analysis:**

The analyst consensus is "Hold" with a wide range in target prices. The average target price ($44.67) suggests some upside potential from the current price, but the large spread between high and low targets indicates uncertainty and differing opinions among analysts.

**5) Recent Earnings Analysis:**

| 날짜       | EPS  | 매출   |
|------------|------|--------|
| 2025-11-03 | 0.07 | 0.60 B$ |
| 2025-08-04 | 0.19 | 0.54 B$ |
| 2025-05-05 | 0.22 | 0.59 B$ |
| 2024-11-04 | 0.35 | 0.40 B$ |
| 2025-11-03 | 0.35 | 0.40 B$ |

**Analysis:**

The EPS (Earnings Per Share) and revenue figures show growth over the past quarters. It indicates a positive trend in the company's financial performance. But in 2025-11-03 the revenue increased whereas the EPS dropped dramatically.

**6) Financial Information:**

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-09-30 | $0.60B  | 73.80%        |
| 2025-06-30 | $0.54B  | 76.39%        |
| 2025-03-31 | $0.59B  | 73.50%        |
| 2024-12-31 | $0.48B  | 76.81%        |
| 2024-09-30 | $0.40B  | 79.16%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE     |
|------------|-----------|---------|
| 2025-09-30 | $0.58B    | 2.72%   |
| 2025-06-30 | $0.56B    | 7.55%   |
| 2025-03-31 | $0.55B    | 9.01%   |
| 2024-12-31 | $0.48B    | 5.46%   |
| 2024-09-30 | $0.44B    | 17.18%  |

**Analysis:**

*   **Revenue:** Revenue has generally been increasing, showing consistent growth.
*   **Profit Margin:** Profit margins are very high, indicating strong pricing power or efficient operations. The profit margins are fluctuating in the 70% range.
*   **Equity:** Equity has been increasing, reflecting the company's growing net worth.
*   **ROE:** Return on Equity (ROE) has been decreasing and has significantly dropped recently, suggesting that the company is not generating as much profit from its equity as before.

**7) Comprehensive Analysis (Summary):**

HIMS has significantly outperformed the S&P 500 in cumulative return, but its historical performance has been volatile, as reflected in its CAGR and MDD.  The recent stock price shows a downtrend. The hybrid signal recommends buying, but analyst consensus is "Hold" with a wide target price range indicating uncertainty. The news is mixed, with positive developments like the share repurchase program and UK expansion offset by articles highlighting recent stock decline. Revenue continues to grow with high profit margins, but the recent dramatic drop in ROE is alarming.

**Overall, the data suggests a mixed outlook for HIMS.** The company has strong growth potential, as indicated by its revenue growth, high profit margins, and international expansion. However, its volatile stock price, declining ROE, and mixed analyst sentiment suggest that it is a risky investment. Recent news of the stock decline adds another layer of concern. Investors should carefully weigh the potential risks and rewards before investing in HIMS.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.